Lipocine releases late breaking presentation on lpcn 1148 phase 2 results at the liver meeting® 2023

Results demonstrate improvements in sarcopenia and other clinically meaningful outcomes patients converting from placebo to lpcn 1148 in the ongoing open label extension also showed improvement in sarcopenia salt lake city , nov. 13, 2023 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders, today announced that results of its phase 2 study evaluating lpcn 1148 are being presented at the american association for the study of liver diseases (aasld) – the liver meeting® 2023, taking place in boston ma. the results are featured in a late-breaking oral presentation and e-poster by dr. arun sanyal, md, director, stravitz-sanyal institute for liver disease and metabolic health, virginia commonwealth university, advisor to lipocine.
LPCN Ratings Summary
LPCN Quant Ranking